Welcome to our dedicated page for Amgen SEC filings (Ticker: AMGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
MILES AMY E reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Amy E. Miles received an equity award of 665 shares of common stock as a grant under the company’s director incentive program. The award, structured as Restricted Stock Units that vested immediately and settle one-for-one in common shares, increased her direct holdings to 5,640 shares. This total includes 408 dividend equivalents credited to her unvested RSUs under a qualifying dividend reinvestment plan.
Kullman Ellen Jamison reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Ellen Jamison Kullman received a grant of 665 shares of common stock as a stock-based award. The award was in the form of Restricted Stock Units (RSUs) under Amgen’s 2009 director incentive and equity incentive plans and vested immediately, with each vested RSU paid in one share of common stock rather than through an open-market purchase.
After this grant, Kullman directly holds a total of 14,535.9807 Amgen shares, which include 2,121 dividend equivalents (DEs) that are credited to her unvested RSUs and will be paid in shares as those RSUs vest, along with cash for any remaining fractional share amount.
Klotman Mary E. reported acquisition or exercise transactions in this Form 4 filing.
Amgen director Mary E. Klotman received an equity award of 665 shares of common stock in the form of Restricted Stock Units. The RSUs were granted under Amgen’s 2009 Director Incentive Program and vested immediately, paying out in common shares on a one-to-one basis.
Following this grant, Klotman directly holds 2,211 shares of Amgen common stock, which include 18 dividend-equivalent units credited to her unvested RSUs under the company’s equity incentive plan.
Jacks Tyler reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Tyler Jacks reported a compensation-related equity grant rather than an open-market trade. He received 665 shares of common stock via immediately vesting Restricted Stock Units under Amgen’s 2009 Director Incentive Program. After this award, he directly holds 18,284 common shares, including 2,975 dividend equivalents tied to unvested RSUs that will be paid in stock as they vest.
ISHRAK OMAR reported acquisition or exercise transactions in this Form 4 filing.
Amgen director Omar Ishrak received a stock grant of 665 shares of common stock as compensation. The award was made as Restricted Stock Units under Amgen’s 2009 director incentive program and vested immediately, with payment in common shares on a one-to-one basis.
After this grant, Ishrak directly holds a total of 7,358.7361 Amgen common shares. Footnotes indicate the total includes 418 dividend equivalents credited to his unvested RSUs, which will also be settled in shares according to their vesting schedule.
Amgen Inc. director Charles M. Holley reported an equity award of 665 shares of common stock, received as a grant of Restricted Stock Units (RSUs) that vested immediately at no cash cost. The RSUs were granted under Amgen’s director incentive program and are settled one-for-one in common shares. Following this grant, Holley holds 12,799.0331 shares directly and an additional 1,260 shares indirectly through the Holley Family Trust. The direct holdings include 1,564 dividend equivalent (DE) units credited on unvested RSUs, which will convert into common shares as those RSUs vest.
Garland Greg C. reported acquisition or exercise transactions in this Form 4 filing.
AMGEN INC director Greg C. Garland received 665 shares of common stock through a stock award. The award was a grant of Restricted Stock Units under Amgen’s director incentive program, which vested immediately and was settled in shares on a one-to-one basis. Following this grant, Garland directly holds 13,848 shares of Amgen common stock.
Amgen Inc. director Robert Eckert received an equity award of 665 shares of common stock on May 19, 2026, reported as a grant or other acquisition at no purchase price. The award came from vested Restricted Stock Units under Amgen’s 2009 director incentive programs and vested immediately.
After this grant, Eckert directly holds 26,251 shares of Amgen common stock. This total includes 3,943 dividend equivalents (DEs) credited to his unvested RSUs under a dividend reinvestment plan, which will pay out in shares as those RSUs vest.
Druker Brian reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Brian Druker received an equity award of 665 shares of Amgen common stock as a grant under the company’s director incentive program. The award was in the form of Restricted Stock Units (RSUs) that vested immediately and are paid in common shares on a one-to-one basis.
Following this grant, Druker directly holds 8,391 shares of Amgen common stock, which include 408 dividend equivalents (DEs) credited to his unvested RSUs under a qualifying dividend reinvestment plan.
Drake Michael V reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Michael V. Drake received 665 shares of common stock as a grant of Restricted Stock Units (RSUs). The RSUs were awarded under Amgen’s 2009 Director Incentive Program and vested immediately, paying out in common shares on a one-to-one basis. Following this award, Drake directly holds about 5,774.2869 Amgen shares, including 339 dividend equivalents credited to his unvested RSUs.